Effect of Dexmedetomidine on Cognitive Dysfunction in Elderly Patients After Surgery
Effect of Dexmedetomidine on Serum Tau-217 Protein as a Biomarker for Post-operative Cognitive Dysfunction in Elderly Patients.
PHASE4 · Minia University Hospital · NCT06366412
This study is testing if the medication dexmedetomidine can help prevent memory problems after major surgery in older patients by looking at certain protein levels in their blood.
Quick facts
| Phase | PHASE4 |
|---|---|
| Study type | Interventional |
| Enrollment | 94 (estimated) |
| Ages | 65 Years and up |
| Sex | All |
| Sponsor | Minia University Hospital (other) |
| Locations | 1 site (Minya) |
| Trial ID | NCT06366412 on ClinicalTrials.gov |
What this trial studies
This study evaluates how dexmedetomidine affects serum Tau-217 protein levels and its relationship with postoperative cognitive dysfunction in elderly patients undergoing major surgery with general anesthesia. It involves measuring serum Tau-217 protein levels before and after surgery and assessing cognitive function in participants. The goal is to determine if dexmedetomidine has a neuroprotective effect that correlates with changes in Tau-217 levels and cognitive outcomes.
Who should consider this trial
Good fit: Ideal candidates are elderly patients over 65 years old, with a Glasgow Coma Scale score of 14-15, undergoing major surgery under general anesthesia.
Not a fit: Patients with severe cardiac, liver, or renal disease, those with Alzheimer's or other psychotic disorders, or those who are poorly educated may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management of postoperative cognitive dysfunction in elderly patients, enhancing their recovery and quality of life.
How similar studies have performed: While there have been studies on dexmedetomidine's effects on cognitive function, the specific focus on serum Tau-217 protein in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged \> 65 years old, both genders, Basal Metabolic Index range 18.5 to less than 35 American Society of Anesthesiologists I - III with Glasgow Coma Scale 14-15 undergoing major surgery under general anesthesia. Exclusion Criteria: * Patients will be excluded if they refused the enrollment in our study, Glasgow Coma Scale\<14 or if there is severe cardiac, liver or renal disease, patients have Alzehimer's Disease or any of the psychotic diseases, poorly educated patients and if there is any sensitivity to given drugs
Where this trial is running
Minya
- Arwa Essam — Minya, Egypt (RECRUITING)
Study contacts
- Study coordinator: Arwa Essam Anwar, Assistant Lecturer
- Email: arwty26@gmail.com
- Phone: +201017565658
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cognitive Impairment, dexmedetomidine, serum Tau-217 protein, cognitive dysfunction